June 24 (Reuters) - Some U.S. stocks on the move on Monday:
U.S. stocks opened sharply lower, extending recent weakness, on concerns the U.S. Federal Reserve’s stimulus may be drawing to a close and that a cash crunch in China could further slow growth. The Dow Jones industrial average was down 0.85 percent, the Standard & Poor’s 500 Index 1.01 percent and the Nasdaq Composite Index 1.10 percent.
** VANGUARD HEALTH SYSTEMS INC, $28.68, up 67 pct (0931 ET)
** TENET HEALTHCARE CORP, $44.18, up 5.5 pct (0931 ET)
U.S. hospital operator Tenet Healthcare will buy smaller rival Vanguard Health Systems for $4.3 billion including debt to expand into new geographies.
** WESTERN DIGITAL CORP, $59.54, down 1 pct (0931 ET)
** STEC INC, $6.73, up 87.6 pct (0931 ET)
Hard disk drive maker Western Digital Corp said it would buy Stec Inc for about $340 million in cash to beef up its solid-state drive business. The offer of $6.85 per share represents a 91 percent premium to Stec’s closing share price on Friday.
** KEYNOTE SYSTEMS INC, $19.80, up 46 pct (0932 ET)
The company, which provides web and mobile cloud monitoring tools, said it would be taken private by an affiliate of private equity firm Thoma Bravo LLC for about $395 million in cash. The $20-per-share offer represents a 48 percent premium to the stock’s closing price on Friday.
The company’s stock has been down 4 percent since the beginning of the year and trades at nearly 20 times forward 12-month earnings, compared with a sector median of about 18.
** ISIS PHARMACEUTICALS INC, $25.42, up 15 pct (0932 ET)
Needham & Co analyst Chad Messer said the company’s program to develop a treatment for hypertriglyceridemia, or high levels of a type of fat, is “one of the more significant of many potential drivers for Isis shareholders over the next 12-18 months.”
Messer added that the data presented from a mid-stage study of the drug was “impressive.”
“We are nonetheless impressed with the ability of the drug to demonstrate such consistent effects in a small study after just 12 weeks of treatment.”
** SOLAZYME INC, $11.10, down 12 pct (0935 ET)
The bioproducts company said it had agreed with Roquette Frères SA, a food ingredient supplier, to dissolve their joint venture, which was set up to develop microalgae-based healthy food ingredients and oils.
Solazyme said the venture was being terminated due to divergent views on an acceptable commercial strategy and timeline for the manufacturing and marketing of joint venture products.
** SAKS INC, $13.62, up 1.7 pct (0936 ET)
The department store operator is a serious acquisition target of Canadian firm Hudson Bay Co, according to retail news website Women's Wear Daily. (r.reuters.com/tef29t)
** ALLERGAN INC, $86.00, down 7 pct (0938 ET)
Sanford C. Bernstein analyst Aaron Gal said the U.S. Food and Drug Administration’s released draft guidance for generic Restasis -- Allergan’s eye drops to treat chronic dry eye disease -- would not be “prohibitively difficult” to execute.
Restasis is Allergan’s second biggest drug and Gal said the FDA had “previously indicated clinical trials would be necessary to obtain approval and such trials are prohibitively expensive.”
** KKR & CO LP, $18.03, down 4 pct (0939 ET)
Funds managed by KKR will buy clinical research group PRA International from Genstar Capital LLC for an undisclosed amount, PRA said on Monday, underscoring growing private equity interest in the contract research industry.
** FACEBOOK INC, $23.58, down 4 pct (0940 ET)
The social network has inadvertently exposed 6 million users’ phone numbers and email addresses to unauthorized viewers over the past year, it disclosed late on Friday.
** CELL THERAPEUTICS INC, $1.06, down 13 pct (0941 ET)
Cell Therapeutics said the U.S. Food and Drug Administration has placed a partial clinical hold on the company’s experimental blood cancer drug after the death of a patient.
** BARRICK GOLD CORP, $16.10, down 5 pct (0941 ET)
The gold producer will lay off up to a third of its corporate staff at its headquarters in Toronto and other offices, sources said, as the world’s top bullion producer intensifies a downsizing plan amid a slump in the price of gold.
** RANDGOLD RESOURCES LTD, $63.88, down 4 pct (0940 ET)
** FREEPORT-MCMORAN COPPER AND GOLD INC, $27.30, down 3 pct (0945 ET)
** GOLDCORP INC, $23.55, down 4 pct (0946 ET)
** ROYAL GOLD INC, $44.80, down 3 pct (0947 ET)
** NEWMONT MINING CORP, $29.11, down 3 pct (0949 ET)
** IAMGOLD CORP, $4.24, down 2.75 pct (0949 ET)
** YAMANA GOLD INC, $9.18, down 3 pct (0950 ET)
Goldman Sachs cut its year-end 2013 gold price forecast to $1,300 an ounce from $1,435, citing a decline in U.S. interest rates as the U.S. Federal Reserve prepares to scale down its stimulus program.
** AMERICAN INTERNATIONAL GROUP INC, $42.48, down 3 pct (0950 ET)
AIG’s unit extended the date for a Chinese consortium to get regulatory approvals to buy the airplane-leasing business till July 31. AIG announced the deal to sell International Lease Finance Corp last December for $4.8 billion to a consortium including New China Trust, one-fifth owned by Barclays Plc , China Aviation Industrial Fund and P3 Investments Ltd.
** APPLE INC, $403.64, down 2 pct (0952 ET)
Chief Executive Tim Cook’s one-time stock award worth over $413 million as of Friday is now partly subject to the performance of the shares, a move that followed discussions with the company’s largest shareholders.
** ORAMED PHARMACEUTICALS INC, $7.12, up 5 pct (0949 ET)
The Israeli drugmaker on Friday pulled a proposed public offering of its common stock due to adverse market conditions. Its stock had lost 36 percent in four days until Thursday.
Oramed is slated to present an abstract titled ‘Dose response to oral insulin capsules in fasting, healthy subjects,’ at the American Diabetes Association from Monday through Friday. (Compiled by Kanika Sikka; Editing by Maju Samuel)